2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101433
    N-Acetylprocainamide hydrochloride 34118-92-8 99.83%
    N-Acetylprocainamide (Acecainide) hydrochloride is a class III antiarrhythmic, which blocks K+ channels.
    N-Acetylprocainamide hydrochloride
  • HY-101436
    Sematilide 101526-83-4 98%
    Sematilide (CK-1752) is a selective IKr channel blocker. Sematilide causes a concentration-dependent inhibition of the delayed rectifier K+ current (IC50=25 μM). Sematilide is a class III antiarrhythmic agent.
    Sematilide
  • HY-101542
    Milfasartan 148564-47-0 98%
    Milfasartan (LR-B/081) is a selective angiotensin receptor AT1 antagonist with antihypertensive activity.
    Milfasartan
  • HY-101602
    Aligeron 70713-45-0 98%
    Aligeron is a non-selective prostaglandin (PG) antagonist, and has vasodilatory properties.
    Aligeron
  • HY-101606
    Etersalate 62992-61-4 98%
    Etersalate inhibits platelet function and decreases thromboxane A2 (TXA2) levels.
    Etersalate
  • HY-101607
    KT-362 105394-80-7 98%
    KT-362 is an intracellular calcium antagonist. KT-362 can inhibit NE-induced contractions and IP accumulation in vivo experiments.
    KT-362
  • HY-10163R
    Dabigatran (Standard) 211914-51-1
    Dabigatran (Standard) is the analytical standard of Dabigatran. This product is intended for research and analytical applications. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
    Dabigatran (Standard)
  • HY-101646
    Saviprazole 121617-11-6
    Saviprazole is a Proton Pump inhibitor. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux.
    Saviprazole
  • HY-101649
    Imiglitazar 250601-04-8 98%
    Imiglitazar (TAK559) is a potent and dual human PPARα and PPARγ1 agonist with EC50 values of 67 and 31 nM.
    Imiglitazar
  • HY-101654
    Rocepafant 132579-32-9 98%
    Rocepafant (BN 50730) is a specific platelet activating factor (PAF) antagonist. Rocepafant can be used in rheumatoid arthritis and nervous system research.
    Rocepafant
  • HY-101675
    Setipafant 132418-35-0 98%
    Setipafant is a platelet-activating factor (PAF) antagonist.
    Setipafant
  • HY-101701
    Hepronicate 7237-81-2 99.95%
    Hepronicate is a peripheral vasodilator with blood lipid lowering action.
    Hepronicate
  • HY-101707
    UK51656 88150-59-8 98%
    UK51656 is a calcium antagonist with IC50 of 4 nM.
    UK51656
  • HY-101740
    SQ-31765 138383-07-0 98%
    SQ-31765 is a benzazepine calcium channel blocker.
    SQ-31765
  • HY-101752
    (±)-Befunolol 39552-01-7 98%
    (±)-Befunolol is a β-adrenoceptor blocking agent.
    (±)-Befunolol
  • HY-101863
    CB-6673567 379218-90-3 98%
    CB-6673567 is a selective AC1 inhibitor with an IC50 of 77 μM .CB-6673567blocks the choline-induced cAMP increase and can be used for cardiovascular diseases research.
    CB-6673567
  • HY-102054
    Acetylhydrolase-IN-1 79637-91-5 98%
    Acetylhydrolase-IN-1 is a 1-Alkyl-2-acetylglycerophosphocholine esterase (Alkylacetyl-GPC: acetylhydrolase) inhibtor.
    Acetylhydrolase-IN-1
  • HY-10274S
    Dabigatran etexilate-d13 2749293-92-1 ≥98.0%
    Dabigatran etexilate-d13 is the deuterium labeled Dabigatran etexilate. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
    Dabigatran etexilate-d13
  • HY-10275A
    Atecegatran TFA 433937-75-8 98%
    Atecegatran TFA (AR-H067637 TFA) is an anticoagulant with selective direct thrombin inhibitory activity. Atecegatran TFA is commonly used to inhibit cardiovascular diseases. The biotransformation product of Atecegatran TFA, AR-H067637, is its active form and participates in the anticoagulation process.
    Atecegatran TFA
  • HY-10304A
    Orbofiban acetate 163250-91-7 98.13%
    Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
    Orbofiban acetate
Cat. No. Product Name / Synonyms Application Reactivity